 BioMarin Pharmaceutical Inc NASDAQ: BMRN reported a 17 YY increase in revenue to 501.7 million in Q2, beating the consensus of 448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues, partially offset by lower Kuvan product revenues. Vimizim and Naglazyme sales increased 47 to 171.7 million and 118.8 million, respectively, primarily driven by the timing of orders from Europe and the Middle East. 